Results 201 to 210 of about 64,891 (274)

Bioipharmaceutical aspects of FK-506 [PDF]

, 1987
Burckart, GJ, Makowka, L, Sanghvi, AT, Selftman, H, Starzl, TE, Todo, S, Venkataramanan, R, Warty, VS, Zemaitis, MA   +8 more
core  

Effects of mallotus furetianus extract on CYP3A activities in rats. [PDF]

Sci Rep
Huang W, Kim HI, Cao F, Li S, Park J, Li P.   +5 more
europepmc   +1 more source

Interaction between crizotinib and tropifexor through <i>in vitro</i> and <i>in vivo</i> studies. [PDF]

PeerJ
Shen A, Xia H, Wu J, Tao L, Chen J, Lin H.   +5 more
europepmc   +1 more source

Unveiling the Endocrine-Disrupting Potential of Plant-Derived Compounds: An Ecotoxicological Review. [PDF]

Toxins (Basel)
Park C, Lim HB.
europepmc   +1 more source

The ontogeny of hepatic cytochrome P450 enzymes in conventional pigs using enzyme activity and proteomics [PDF]

, 2017
Croubels, Siska, Deforce, Dieter, Devreese, Mathias, Gasthuys, Elke, Millecam, Joske, Van Bocxlaer, Jan   +5 more
core   +1 more source

The neuroendocrine regulation of hepatic cytochrome P450 by N-methyl-D-aspartate receptors in the paraventricular and arcuate nuclei of the hypothalamus. [PDF]

Drug Metab Dispos
Pukło R, Bromek E, Basińska-Ziobroń A, Haduch A, Kuban W, Danek PJ, Daniel WA.   +6 more
europepmc   +1 more source

Covalently Active Metabolites of Bisphenol A Analogs by Mass Spectrometry Diagnostic Ions: Possible Mechanisms of Their Toxicity. [PDF]

Chem Res Toxicol
He Q, Hu X, Li X, Li N, Wu JL.
europepmc   +1 more source

Use of a cytochrome P450 humanised mouse model to refine schistosomiasis drug discovery

Davey SD, Forde-Thomas JE, Hulme BJ, Lees K, Costain AH, Evans M, Rinaldi G, Frame L, Stojanovski L, Simeons FRC, Tavendale A, Kenneth MacLeod A, Pichon R, Lee Y, Polak O, Chalmers IW, Dankwa B, Odhiambo BK, Guimaraes VH, Hegarty M, Swain MT, Aubrey W, Caldwell N, MacDonald AS, Gilbert IH, Baragaña B, Read KD, Hoffmann KF.   +27 more
europepmc   +1 more source

Erratum to "Inhibitory effects of Δ8-tetrahydrocannabinol on major hepatic cytochrome P450 enzymes and implications for drug disposition" [Drug Metabolism and Disposition 53 (2025) 100122]. [PDF]

Drug Metab Dispos
Zhao M, Coates S, Bardhi K, Lazarus P.
europepmc   +1 more source

Development and validation of a UPLC-MS/MS method for the quantification of asciminib and its pharmacokinetic interaction and metabolic stability with shikonin. [PDF]

BMC Pharmacol Toxicol
Zhou C, Xia H, Hu Y, Chen X, Zou Q, Xu X, Jiang ZL.   +6 more
europepmc   +1 more source